Published in Antimicrob Agents Chemother on October 07, 2013
Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children. J Infect Dis (2014) 2.28
Role of Pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine, and dihydroartemisinin. Antimicrob Agents Chemother (2014) 0.91
Temporal trends in prevalence of Plasmodium falciparum drug resistance alleles over two decades of changing antimalarial policy in coastal Kenya. Int J Parasitol Drugs Drug Resist (2014) 0.85
Molecular epidemiology and seroprevalence in asymptomatic Plasmodium falciparum infections of Malagasy pregnant women in the highlands. Malar J (2015) 0.80
Theileria equi isolates vary in susceptibility to imidocarb dipropionate but demonstrate uniform in vitro susceptibility to a bumped kinase inhibitor. Parasit Vectors (2015) 0.79
Prevalence of anti-malarial resistance genes in Dakar, Senegal from 2013 to 2014. Malar J (2016) 0.76
Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate-amodiaquine fixed dose combination or artemether-lumefantrine in Liberia. Malar J (2016) 0.75
Failure of dihydroartemisinin plus piperaquine treatment of falciparum malaria by under-dosing in an overweight patient. Malar J (2016) 0.75
Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2009) 33.25
Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet (2012) 11.82
A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med (2001) 9.18
Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature (2000) 8.46
A major genome region underlying artemisinin resistance in malaria. Science (2012) 6.25
In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis (2005) 6.13
Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci (1999) 4.52
Impact of chloroquine resistance on malaria mortality. C R Acad Sci III (1998) 4.41
The past, present and future of childhood malaria mortality in Africa. Trends Parasitol (2001) 4.10
The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol Biochem Parasitol (2000) 4.08
Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis (2010) 3.59
Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp Parasitol (1998) 3.43
Dissecting the loci of low-level quinine resistance in malaria parasites. Mol Microbiol (2004) 3.30
Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother (2006) 3.10
Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Chemother (2012) 3.01
In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis (2009) 2.80
Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother (2006) 2.74
Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum. Mol Microbiol (2000) 2.62
In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother (2009) 2.36
Analysis of pfmdr1 and drug susceptibility in fresh isolates of Plasmodium falciparum from subsaharan Africa. Mol Biochem Parasitol (1995) 2.29
Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother (2008) 2.27
High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. PLoS One (2009) 2.18
The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop Med Int Health (2007) 2.17
Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am J Trop Med Hyg (2008) 1.95
Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. J Infect Dis (2011) 1.94
In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. Int J Parasitol (1996) 1.90
Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Antimicrob Agents Chemother (2006) 1.89
Online analysis of in vitro resistance to antimalarial drugs through nonlinear regression. Comput Methods Programs Biomed (2010) 1.85
Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. Infect Genet Evol (2007) 1.84
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother (2010) 1.83
Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics (2001) 1.83
Diversity of the sarco/endoplasmic reticulum Ca(2+)-ATPase orthologue of Plasmodium falciparum (PfATP6). Infect Genet Evol (2008) 1.80
Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of the Congo. J Clin Microbiol (2006) 1.74
In vitro study of drug sensitivity of Plasmodium falciparum: evaluation of a new semi-micro test. Am J Trop Med Hyg (1983) 1.69
Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr Opin Infect Dis (2011) 1.68
Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. Antimicrob Agents Chemother (2008) 1.65
A shared Asian origin of the triple-mutant dhfr allele in Plasmodium falciparum from sites across Africa. J Infect Dis (2007) 1.61
Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther (2002) 1.52
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother (2010) 1.49
Monitoring for Plasmodium falciparum drug resistance to artemisinin and artesunate in Binh Phuoc Province, Vietnam: 1998-2009. Malar J (2010) 1.45
Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda. Antimicrob Agents Chemother (2007) 1.44
Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine. Antimicrob Agents Chemother (2011) 1.32
Dramatically decreased therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine, but not mefloquine, in southern Benin. Trop Med Int Health (2007) 1.30
A comparison of the in vitro activities of amodiaquine and desethylamodiaquine against isolates of Plasmodium falciparum. Am J Trop Med Hyg (1989) 1.27
Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms. J Infect Dis (2012) 1.26
Plasmodium falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa. J Infect Dis (2009) 1.26
Molecular markers of resistance to sulphadoxine-pyrimethamine during intermittent preventive treatment of pregnant women in Benin. Malar J (2011) 1.21
Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty. Malar J (2010) 1.20
In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaoundé, Cameroon. Antimicrob Agents Chemother (1998) 1.20
In vitro activity of monodesethylamodiaquine and amopyroquine against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg (1993) 1.02
Polymorphism in PfMRP1 (Plasmodium falciparum multidrug resistance protein 1) amino acid 1466 associated with resistance to sulfadoxine-pyrimethamine treatment. Antimicrob Agents Chemother (2009) 1.01
Update on genetic markers of quinine resistance in Plasmodium falciparum. Mol Biochem Parasitol (2011) 0.97
Short report: lack of prediction of amodiaquine efficacy in treating Plasmodium falciparum malaria by in vitro tests. Am J Trop Med Hyg (2004) 0.88
pfmdr1 mutations in imported African Plasmodium falciparum isolates. Trans R Soc Trop Med Hyg (2008) 0.85
Effectiveness of co-trimoxazole to prevent Plasmodium falciparum malaria in HIV-positive pregnant women in sub-Saharan Africa: an open-label, randomized controlled trial. Clin Infect Dis (2013) 2.80
The clinical spectrum of severe imported falciparum malaria in the intensive care unit: report of 188 cases in adults. Am J Respir Crit Care Med (2002) 2.79
Severe falciparum malaria in Gabonese children: clinical and laboratory features. Malar J (2005) 2.35
Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar J (2009) 2.33
High level of var2csa transcription by Plasmodium falciparum isolated from the placenta. J Infect Dis (2005) 1.90
Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Antimicrob Agents Chemother (2006) 1.89
Congenital parasitic infections: a review. Acta Trop (2011) 1.88
Predictive factors of malaria in travelers to areas where malaria is endemic. Arch Intern Med (2002) 1.86
Severe imported falciparum malaria: a cohort study in 400 critically ill adults. PLoS One (2010) 1.86
Online analysis of in vitro resistance to antimalarial drugs through nonlinear regression. Comput Methods Programs Biomed (2010) 1.85
Influence of the timing of malaria infection during pregnancy on birth weight and on maternal anemia in Benin. Am J Trop Med Hyg (2011) 1.80
Decreased in vitro susceptibility of Plasmodium falciparum isolates to artesunate, mefloquine, chloroquine, and quinine in Cambodia from 2001 to 2007. Antimicrob Agents Chemother (2010) 1.76
Epitope mapping and topographic analysis of VAR2CSA DBL3X involved in P. falciparum placental sequestration. PLoS Pathog (2006) 1.76
Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. J Infect Dis (2009) 1.75
Plasmodium falciparum clonal population dynamics during malaria treatment. J Infect Dis (2004) 1.74
Evaluation of the intra- and inter-specific genetic variability of Plasmodium lactate dehydrogenase. Malar J (2007) 1.71
Prevalence of Plasmodium falciparum infection in pregnant women in Gabon. Malar J (2003) 1.70
Malaria infection and disease in an area with pyrethroid-resistant vectors in southern Benin. Malar J (2010) 1.59
Increased prevalence of intestinal helminth infection during pregnancy in a Sub-Saharan African community. Wien Klin Wochenschr (2007) 1.58
Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. Microbes Infect (2006) 1.56
Assessment of volume depletion in children with malaria. PLoS Med (2004) 1.51
Invasion of Africa by a single pfcrt allele of South East Asian type. Malar J (2006) 1.51
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg (2014) 1.51
Chimpanzee malaria parasites related to Plasmodium ovale in Africa. PLoS One (2009) 1.49
Imported malaria in HIV-infected patients enrolled in the ANRS CO4 FHDH study. J Acquir Immune Defic Syndr (2008) 1.46
Hospitalization criteria in imported falciparum malaria. J Travel Med (2007) 1.45
Rapid dissemination of Plasmodium falciparum drug resistance despite strictly controlled antimalarial use. PLoS One (2007) 1.44
World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility. Malar J (2007) 1.41
[Rapid detection of malaria and P. falciparum chemoresistant genotypes in Mayotte, 2001]. Presse Med (2002) 1.41
Resistance to dihydroartemisinin. Emerg Infect Dis (2006) 1.40
Evidence of decline of malaria in the general hospital of Libreville, Gabon from 2000 to 2008. Malar J (2009) 1.40
Does modulation of organic cation transporters improve pralidoxime activity in an animal model of organophosphate poisoning? Crit Care Med (2011) 1.39
Do African immigrants living in France have long-term malarial immunity? Am J Trop Med Hyg (2005) 1.39
Bringing antivenoms to Sub-Saharan Africa. Nat Biotechnol (2007) 1.38
Risk factors for imported fatal Plasmodium falciparum malaria, France, 1996-2003. Emerg Infect Dis (2007) 1.37
Can treatment of malaria be restricted to parasitologically confirmed malaria? A school-based study in Benin in children with and without fever. Malar J (2010) 1.36
Variable adhesion abilities and overlapping antigenic properties in placental Plasmodium falciparum isolates. J Infect Dis (2004) 1.36
Combined deletions of pfhrp2 and pfhrp3 genes result in Plasmodium falciparum malaria false-negative rapid diagnostic test. J Clin Microbiol (2011) 1.34
Intermittent preventive treatment for the prevention of malaria during pregnancy in high transmission areas. Malar J (2007) 1.34
Dramatically decreased therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine, but not mefloquine, in southern Benin. Trop Med Int Health (2007) 1.30
PfHRP2 and PfLDH antigen detection for monitoring the efficacy of artemisinin-based combination therapy (ACT) in the treatment of uncomplicated falciparum malaria. Malar J (2009) 1.29
Maternal anemia in Benin: prevalence, risk factors, and association with low birth weight. Am J Trop Med Hyg (2011) 1.27
Efficacy of intermittent preventive treatment versus chloroquine prophylaxis to prevent malaria during pregnancy in Benin. J Infect Dis (2008) 1.26
Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children. Antimicrob Agents Chemother (2003) 1.24
The sickle cell trait is associated with enhanced immunoglobulin G antibody responses to Plasmodium falciparum variant surface antigens. J Infect Dis (2005) 1.23
Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. J Antimicrob Chemother (2005) 1.23
Molecular markers of resistance to sulphadoxine-pyrimethamine during intermittent preventive treatment of pregnant women in Benin. Malar J (2011) 1.21
Prevention of malaria during pregnancy: assessing the effect of the distribution of IPTp through the national policy in Benin. Am J Trop Med Hyg (2011) 1.21
Plasmodium falciparum genotype population dynamics in asymptomatic children from Senegal. Microbes Infect (2006) 1.18
High efficacy of anti DBL4ɛ-VAR2CSA antibodies in inhibition of CSA-binding Plasmodium falciparum-infected erythrocytes from pregnant women. Vaccine (2010) 1.18
In vitro susceptibility to a new antimalarial organometallic analogue, ferroquine, of Plasmodium falciparum isolates from the Haut-Ogooué region of Gabon. J Antimicrob Chemother (2003) 1.17
Differences in presentation of severe malaria in urban and rural Gabon. Am J Trop Med Hyg (2007) 1.17
Human neurocysticercosis: comparison of different diagnostic tests using cerebrospinal fluid. J Clin Microbiol (2010) 1.16
DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy. J Antimicrob Chemother (2003) 1.16
High-throughput analysis of antimalarial susceptibility data by the WorldWide Antimalarial Resistance Network (WWARN) in vitro analysis and reporting tool. Antimicrob Agents Chemother (2013) 1.15
Severe imported Plasmodium falciparum malaria, France, 1996-2003. Emerg Infect Dis (2011) 1.15
Polymorphism in two merozoite surface proteins of Plasmodium falciparum isolates from Gabon. Malar J (2003) 1.15
Parallel evolution of adaptive mutations in Plasmodium falciparum mitochondrial DNA during atovaquone-proguanil treatment. Mol Biol Evol (2007) 1.13
Infections in infants during the first 12 months of life: role of placental malaria and environmental factors. PLoS One (2011) 1.12
Epidemiology of drug-resistant malaria in Republic of Congo: using molecular evidence for monitoring antimalarial drug resistance combined with assessment of antimalarial drug use. Trop Med Int Health (2005) 1.12
IL-12 producing monocytes and IFN-gamma and TNF-alpha producing T-lymphocytes are increased in placentas infected by Plasmodium falciparum. J Reprod Immunol (2006) 1.12
Prolonged Plasmodium falciparum infection in immigrants, Paris. Emerg Infect Dis (2008) 1.10
Baseline in vitro efficacy of ACT component drugs on Plasmodium falciparum clinical isolates from Mali. Int J Parasitol (2008) 1.09
Increase in malaria prevalence and age of at risk population in different areas of Gabon. Malar J (2013) 1.08
First-trimester Plasmodium falciparum infections display a typical "placental" phenotype. J Infect Dis (2012) 1.07
The Lambaréné Organ Dysfunction Score (LODS) is a simple clinical predictor of fatal malaria in African children. J Infect Dis (2009) 1.07
Leishmania resistance to miltefosine associated with genetic marker. Emerg Infect Dis (2012) 1.07
Comparison of PCR-based detection of Plasmodium falciparum infections based on single and multicopy genes. Malar J (2007) 1.07
Maternally transmitted antibodies to pregnancy-associated variant antigens on the surface of erythrocytes infected with Plasmodium falciparum: relation to child susceptibility to malaria. Am J Epidemiol (2003) 1.06
Malaria, from natural to supernatural: a qualitative study of mothers' reactions to fever (Dienga, Gabon). J Epidemiol Community Health (2004) 1.05
Maternal anemia at first antenatal visit: prevalence and risk factors in a malaria-endemic area in Benin. Am J Trop Med Hyg (2012) 1.05
Impact of long-lasting, insecticidal nets on anaemia and prevalence of Plasmodium falciparum among children under five years in areas with highly resistant malaria vectors. Malar J (2014) 1.05
Demonstration of a high level of parasite population homology by quantification of Plasmodium falciparum alleles in matched peripheral, placental, and umbilical cord blood samples. J Clin Microbiol (2005) 1.05
PftetQ and pfmdt copy numbers as predictive molecular markers of decreased ex vivo doxycycline susceptibility in imported Plasmodium falciparum malaria. Malar J (2013) 1.05
Use of antivenoms for the treatment of envenomation by Elapidae snakes in Guinea, Sub-Saharan Africa. J Venom Anim Toxins Incl Trop Dis (2013) 1.04
Is chloroquine chemoprophylaxis still effective to prevent low birth weight? Results of a study in Benin. Malar J (2007) 1.04